IMPORTANCE Survivorship involves a multidisciplinary approach to surveillance and management of comorbidities and secondary cancers, overseen by oncologists, surgeons, and primary care physicians. Optimal timing and coordination of care, however, is unclear and often based on arbitrary 5-year cutoffs.
W ith increasing cancer incidence and improved therapies, the population of cancer survivors has increased substantially. There are more than 15 million individuals living with a cancer diagnosis in the United States, and this number is estimated to reach 20.3 million by 2026.
1,2 In a 2005 report, the Institute of Medicine chronologically defined cancer survivorship as the period spanning diagnosis, initial treatment, and eventual palliative treatment.
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Care should meet the following goals: (1) prevention of primary recurrence, (2) surveillance of primary cancer and identification of secondary cancers and late effects, (3) interventions addressing the late treatment effects and comorbidities, and (4) coordination of care. 3(p3) Survivorship care coordination involves shifting resources and leadership between the patient's primary care physician, medical oncologist, radiation oncologist, oncologic surgeon, medical subspecialists, and other allied health professionals. This has led to a diverse array of delivery systems of survivorship care, which have been studied. 4, 5 No clear or universal guidance exists for the transition from oncologist-coordinated care to primary care physician-coordinated care for most cancers. This is, in part, due to the unique natural history across tumor types, as well as the availability of effective treatment assets and likelihood of response to therapy, which can influence mortality over time from initial diagnosis. A risk-stratified approach to survivorship care could identify patients with select cancers who would be well suited for primary physician-led care 6 ; however, these models have only been developed for select cancer types and do not have methods that could be universally applied.
5 Arguments have even been made that certain low-risk cancers may not require any follow-up with an oncologist. 7 Thus, it is crucial to accurately characterize survival trajectories across tumor subtypes to allow for personalized and data-driven survivorship care planning. The objective of this longitudinal descriptive study was to establish data-informed, tumor-specific boundaries representing different phases of survivorship. Establishing standardized nomenclature for survival trajectories can offer justification for different physicians coordinating survivorship care at different points. Using mortality estimates relative to the general population provides an important benchmark to estimate key periods of cancer survivorship. In this manner, a high-risk period (ie, increased risk of death in the next year) and cancer type (risk cluster) would dictate intensive oncologist-led followup, which could be led by a primary care physician once a patient reaches a defined lower-risk period that is dominated by secondary cancers, late-treatment effects, comorbidities, and other environmental factors. We addressed this objective using survival data obtained from the Surveillance, Epidemiology, and End Results (SEER) database in a pan-cancer approach, examining trajectories across 66 different tumor types. We quantified 2 key features of cancer survivorship: (1) the time to reach a stable mortality risk and (2) the amount of increased mortality above the baseline mortality of a general control population. Tumors were then grouped into high-and low-risk clusters based on the duration and extent of elevated mortality risk. To further clarify mortality risks, we defined the risk of primary cancer-related mortality vs other cause mortality.
Methods

Cohort Definition
This study was exempt from institutional review board approval and informed consent waived owing to its use of retrospectively collected, publicly available data. We used SEER version 9 data, which include a population-based sample of US cancer cases diagnosed from 1973 to 2013. We included patients with incident cancer younger than 100 years, and excluded those who had a survival or follow-up time less than 1 month, were missing age or survival data, had a prior personal history of cancer, had "lymph node" or "hematologic" primary malignant neoplasms, or if the tumor-type group had fewer than 200 cases (for a robust survival analysis). The cases were grouped using tissue type categories based on the International Classification of Diseases for Oncology (ICD-O-3) codes. Baseline demographic characteristics were recorded for each tumor type, including malignant spread at time of diagnosis (localized vs distant). Primary treatment of surgery or radiation therapy was noted; however, chemotherapy data are not available in SEER.
Outcome: Conditional Probability of Death
Overall survival was defined as the duration of the interval from diagnosis to death or end of follow-up, depending on the vital status noted in SEER. Our approach assessed the conditional probability of death within 1 year in the at-risk population. This annualized mortality risk is similar to the instantaneous hazard function used in Kaplan-Meier analyses but does not exceed 1.0. The conditional probability of death was calculated as P(t ≤ T<t + Δt|T≥t)=[S(t)−S(t +Δt)]/S(t), where Δt = 1 year, and S(t) is the Kaplan-Meier survival function at time t. This is a discrete version of the instantaneous hazard function used in Cox proportional hazard models. We calculated the conditional probability of death within 1 year in the normal population based on the US Census life tables released in 2011, 8 matched to the cancer population by age and sex. After computing the annualized conditional probabilities, we fit the probabilities with a cubic smoothed spline curve, and used bootstrap resampling to compute 95% confidence intervals.
Defining the High-Risk Period for Increased Mortality
For most cancer types, mortality peaks soon after diagnosis, gradually decreases, and plateaus near that of the general population. 2 We separated this follow-up time into 2 periods: a high-risk period with elevated but decreasing annualized mortality and a stable period with lower and steady annualized mortality, which is close to but never meets that of the general population. This transition from the high-risk to stable period was calculated as the point at which the year-to-year difference of the annualized mortality gap between the cancer population and the age-and sex-matched controls changed less than an arbitrarily chosen α = 0.003 cutoff to reliably define the stable period.
Annualized Mortality Gap in the Stable Period
After defining the high-risk and low-risk periods, we calculated the "mortality gap" in the low-risk period. This was reported as the median percent annualized mortality above that of the age-and sex-matched controls in the stable period.
Hierarchical Clustering
We performed hierarchical clustering analyses using data from the first 10 years of follow-up after diagnosis, which includes both the high-risk and stable periods for the majority of cancer subtypes. We used a Euclidean distance metric and the Ward minimum variance-linkage method to cluster the different tissue types, 9 on both the high-risk period duration and the annualized mortality gap, to create clusters of cancers that could be ranked from highest to lowest high-risk duration and elevated annualized mortality risk.
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Subgroup Analyses
This pan-cancer analysis did not consider tumor characteristics that are known to influence recurrence and mortality, such as stage and histologic type. To demonstrate the effect of cancer stage, the analyses were repeated after first stratifying on stage.
Stage was determined as localized/regional, distantly metastatic, or unstaged as determined by SEER summary staging. A subanalysis of each histologic subtype of all SEER cancers could not be performed and reported efficiently for each cancer type, so we performed this analysis for ovarian cancer as an example. We calculated the high-risk duration and mortality gap for each most common ICD-O-3 histology codes for ovarian cancer: serous, clear cell, endometrioid, and mucinous ovarian cancers. A permutation t test and Cox proportional hazard models were used to determine whether these stratifications resulted in statistically significant model improvement.
Cancer vs Other Cause Mortality
The most common causes of mortality in the cancer survivor populations were reported: primary cancer, secondary cancer, cardiac disease, and all other causes as reported by SEER.
To determine the relative contribution of primary cancerspecific mortality in defining a high-risk period duration, we documented the length of the period during which primary cancer mortality was the leading (>50%) contributor to observed mortality, if ever, and reported this as the "cause of death high-risk period."
Results
The SEER database contained data on 2 999 994 people with documented malignant neoplasms. After applying exclusion criteria, 2 317 185 with complete data were available for analysis ( Figure 1 ). The final cancer population had a median age of 63 years and was 49.8% female and 83.4% white ( Table 1 and eTable 1 in the Supplement). Total follow-up time ranged from 1 month to 21 years, and 63.6% of patients died during followup. A total of 13% had distant disease, 64.0% required surgery, and 27.2% underwent radiation therapy. The cases were sorted into 66 different cancer populations, ranging in size from n = 211 for pituitary gland cancer cases to n = 206 889 for prostate cancer cases.
As an example of the performed high-risk duration analysis (fully outlined in eFigure 1 in the Supplement), Figure 2 shows a graphical representation of the age-and sexmatched annualized mortality gap in ovarian cancer. Annualized mortality was at maximum immediately following diagnosis, then rapidly decreased over 9 years until it reached stability, defining a 9-year high-risk period. The annualized mortality gap in the stable period remained elevated above the age-and sex-matched control baseline, demonstrating a median mortality gap elevation of 1.2%.
We used this approach for each tumor type. This resulted in a range of high-risk period durations from under 1 year (breast, prostate, lip, ocular, parathyroid cancer populations) to 19 years (unspecified gastrointestinal cancers), reported in eTable 2 in the Supplement. The annualized mortality gap, representing the excess mortality in the stable period, ranged from a median 0.26% to 9.33% excess annual mortality (thyroid and hypopharyngeal cancer populations, respectively). Details for the most common cancers are reported in Table 2 . Using both the morphology and size of this mortality gap, cancers were grouped into 6 clusters ( Table 3) . The annualized mortality gaps for each of the 66 tumor types are shown in eFigure 2 in the Supplement, color-coded by cluster. The lowest-risk cluster 1, which included 18 cancers (eg, breast, prostate, skin), demonstrated a short time to stability (median, 2.5 years) and lower excess mortality (median, 1.4%). Increasing cluster numbers had longer times to stability and increasing excess baseline mortality. For example, the largest mortality gap was observed in cluster 4 (median, 6.1%) and included oral and pharyngeal cancer populations, while the longest highrisk period was observed for cluster 6, which included 3 cancer populations (pancreas, intrahepatic bile duct, and pleural cancer), with a median of 12.0 years.
When stratifying tumors by metastatic vs local disease spread, differences were observed, although many strata were too small to analyze (eTable 2 in the Supplement). The assigned risk cluster was higher in the metastatic clusters for all cancers except retroperitoneal/peritoneal, nasal cavity, pleural, and nasopharyngeal cancers, although the high-risk duration was longer in the metastatic subgroup for each. In the example secondary analysis of ovarian cancer histological subtypes, serous ovarian cancers, known to have a poorer survival, 10 emerged as having a longer high-risk period than other histologic subtypes (eFigure 3 in the Supplement). The causes of death from primary cancer are reported for each cancer (Table 2 and eTable 2 in the Supplement) and cluster (Table 3) , reporting the year at which primary cancer mortality was no longer above 50% of mortality. Death was observed in 63.4% of the entire cancer survivor population, with primary cancer as the leading cause of death (47.9%), followed by other causes (21.7%), secondary cancer (16.7%), and cardiac disease (13.7%) (eTable 2 in the Supplement). Primary cancer was the leading cause of death at some point in a majority of the tumor-specific survivor populations (36 [55%] ). In those 36 cancer types, the primary cancer-specific cause of death high-risk period ranged from 0 to 13 years, highest for survivors of the group of brain, central nervous system, or spine malignant neoplasms. This cause-specific method of determining the high-risk period tended to produce a high-risk period that was shorter than that defined by the overall mortality gap analysis, except in breast, retina, brain, central nervous system, and spine, and pineal gland cancer survivor popula- tions. This cause-specific method was also performed on a stage-stratified basis and is reported in Table 2 and eTable 2 in the Supplement. Similar to the overall mortality gap determination of the high-risk periods, the cause of deathdetermined high-risk period was longer for metastatic vs localized cancer survivor populations.
Discussion
This study developed and implemented a novel analytic method to classify the highest-risk periods for a multitude of tumor types and to quantify the amount of elevated risk in mortality above that of the general population during the stable period. This extends our understanding of cancer survival trajectories beyond the simple 5-year mortality metric or risk of recurrence. The durations of high-risk periods serve as useful cutoffs to define long-term cancer survivors, who represent an important group to study and understand the underlying factors. 11 We then used clustering methods to identify a group of lowest-risk cancer types (ie, short highrisk period of cancer-related death and small mortality gap compared with the general population), as well as groups of high-risk cancer types (ie, long duration of high-risk period and/or large mortality gap). This importantly defines the period when cancer survivor populations might benefit from greater oncology involvement. The cause of death analysis also identifies the large group of cancer survivor populations who never have primary cancer as the leading cause of death, and could have these risks addressed by their primary care physician in shared care, and/or specialists such as cardiologists, oncocardiologists, and others to address their comorbidities and treatment-related effects. 12 Risk clusters 3, 4, 5, and 6 all had high-risk periods longer than 5 years, the highest mortality gap percentage in the stable period, and had primary and secondary cancers contribute to the majority of observed deaths; this argues that they would benefit most from greater oncology involvement. Cluster 1 had the lowest high-risk period duration and median mortality gap, and had cardiac and other causes contributing to a majority of deaths. This cluster had the most surgical management (86.3%), and represents cancer populations that would benefit from early primary care physician-led care after curative cancer treatment from the oncologist and surgical team. Specific subtypes of each cancer may fall into different risk clusters based on the mortality gap and high-risk period, warranting further study based on type-specific criteria (eg, histologic type, expression of certain tumor markers, grade). The stage-stratified analyses suggest that the localized vs metastatic dichotomy informs the high-risk duration and risk cluster category. Breast cancer populations with metastatic disease, for instance, had a much longer high-risk duration (17 vs 0 years), and existed in risk cluster 2 among metastatic cancers, suggesting that they are a subpopulation whose care plans require a more tailored approach. Pancreatic cancer, however, remained in the highest-risk cluster 6 regardless of stratification. The histology-stratified ovarian cancer example demonstrated that different histologic sub- 
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Defining Survivorship Trajectories Across Patients With Solid Tumors types can fall within different risk clusters. These subanalyses wholly demonstrate that there are a number of potential subpopulations for each tumor that may have different highrisk period durations, elevated mortality risk, or risk cluster classification. Although an exhaustive analysis of these tumor subtypes is beyond the scope of this article, the mortality-based clusters provide robust, broad, and accessible categories. We have provided our analysis code so the analysis could be performed for tumors of interest after accessing SEER data using analysis code in R (https://github .com/zhaozhangyangzi/SEER_survivorship.git). This study additionally identified patients with cancer who have highly increased mortality not due to the primary cancer in the stable period, who could benefit from intense interventions to mitigate posttreatment effects, secondary cancers, and other comorbidities. The cause of death analysis showed that just over half of the cancer populations had their primary cancer as the leading cause of death in the observed follow-up period. This adult study contrasts with an investigation of causes of death of childhood cancer survivors, where primary cancer recurrence remained the leading cause of death even decades after diagnosis. 13 Our study emphasizes the need to focus resources in the survivorship period on other causes of mortality such as comorbidities and heart disease, as well as secondary cancers and treatment effects. The strengths of this study include its scope and longterm follow-up provided by the SEER database to inform nearly every solid-tumor survivor population in the United States. The use of overall mortality is the most universal approach to incorporate cancer recurrence and mortality, treatment effects, secondary cancer risks, comorbidities, and other related environmental factors, although in a nonspecific manner. This can address the diverse patients encountered by oncologists and primary care physicians. Our analysis uses an unbiased, universal, and reproducible approach relying on mortality data to group cancer survivor populations into clusters of increasing risk, whose survivorship care can then be tailored to the unique care delivery system available to each patient. The additional information provided by the stratified analysis based on stage and the cause of death data can further personalize survivorship care when sufficient resources are available.
Limitations
The exhaustive pan-cancer analysis does serve as a weakness to the study, in that it is not possible to report on specific stage, grade, and histologic type subpopulations within the scope of a single report. The SEER data do not report specific details such as chemotherapy administration, which could further inform late-term treatment effects leading to mortality. Additionally, our primary mortality-based cluster analysis incorporates the balance of cancer mortality and nonprimary cancer mortality. However, the reported cause of death secondary analysis findings appear to confirm the cluster's ability to identify populations that could benefit from more oncologist-led or more primary care-led survivorship care. This mortality-based approach also does not address morbidity, as SEER does not contain patient-reported outcomes, or costs.
Conclusions
The analyses presented herein could inform evidence-based follow-up guidelines in the United States and worldwide, and also demonstrate that survivorship care should be individualized on patient-level factors such as stage and histologic subtype. However, additional work is needed to further define survivorship trajectories specifically for subpopulations with characteristics known to influence prognosis.
Better guidelines and care planning can lead to more efficient allocation of public health resources, as well as balancing the time, and insurance reimbursements for care led by oncologists, oncologic surgeons, primary care physicians, medical subspecialists, and allied health professionals. We believe that this pan-cancer analysis can be used to inform explicit and evidence-based survivorship care planning that maximizes both survival and delivery of high-quality cancer survivorship care. Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. COD=Cause of death; NOS=Not otherwise specified. Note some cases were unstaged so stratified analysis may not add to the total.
